Review Cardiovascular & Renal; Recent Developments in Glycoprotein llb/llla Antagonists

Abstract

Platelet adhesion and aggregation, which have been identified as promising targets for the development of antithrombotic drugs, are mediated by a family of glycoprotein receptors. Antagonists of the most important of these receptors, Gpllb/llla, are currently under investigation for a range of both cardiovascular and cerebrovascular disorders. This article aims to compare data for existing Gpllb/llla antagonists in various stages of clinical development, with those compounds which appear in the recent patent literature.